Correspondence 0001654954-24-001303 from TENAX THERAPEUTICS, INC. (TENX)
TENAX THERAPEUTICS, INC.
Date: Feb. 5, 2024 · CIK: 0000034956 · Accession: 0001654954-24-001303
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-275856
Letter
tenx_corresp.htmTENAX THERAPEUTICS, INC.
101 Glen Lennox Drive, Suite 300
Chapel Hill, North Carolina 27517
February 5, 2024
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention:
Mr. Daniel Crawford
Division of Corporation Finance
Office of Life Sciences
Re:
Acceleration Request
Tenax Therapeutics, Inc.
Registration Statement on Form S-1
Filed December 1, 2023, as amended on February 1 and 2, 2024
(File No. 333-275856)
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Tenax Therapeutics, Inc. (the “Registrant”) hereby requests that the U.S. Securities and Exchange Commission (the “Commission”) take appropriate action to accelerate the effective date of the above-referenced registration statement (the “Registration Statement”) so as to become effective on Tuesday, February 6, 2024, at 5:30 p.m. Eastern Time, or as soon thereafter as practicable or at such later time as the Registrant or its counsel may orally request via telephone call to the staff of the Commission.
The Registrant hereby authorizes Lorna A. Knick and/or S. Halle Vakani of Wyrick Robbins Yates & Ponton LLP to orally modify or withdraw this request for acceleration.
Once the Registration Statement is effective, please orally confirm the event with our counsel, Wyrick Robbins Yates & Ponton LLP, by calling Lorna A. Knick (919) 865-2823. We also respectfully request that a copy of the written order from the Commission verifying the effective date and time of the Registration Statement be sent to Ms. Knick via email at lknick@wyrick.com.
Very truly yours,
TENAX THERAPEUTICS, INC.
Show Raw Text
CORRESP
1
filename1.htm
tenx_corresp.htmTENAX THERAPEUTICS, INC.
101 Glen Lennox Drive, Suite 300
Chapel Hill, North Carolina 27517
February 5, 2024
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention:
Mr. Daniel Crawford
Division of Corporation Finance
Office of Life Sciences
Re:
Acceleration Request
Tenax Therapeutics, Inc.
Registration Statement on Form S-1
Filed December 1, 2023, as amended on February 1 and 2, 2024
(File No. 333-275856)
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Tenax Therapeutics, Inc. (the “Registrant”) hereby requests that the U.S. Securities and Exchange Commission (the “Commission”) take appropriate action to accelerate the effective date of the above-referenced registration statement (the “Registration Statement”) so as to become effective on Tuesday, February 6, 2024, at 5:30 p.m. Eastern Time, or as soon thereafter as practicable or at such later time as the Registrant or its counsel may orally request via telephone call to the staff of the Commission.
The Registrant hereby authorizes Lorna A. Knick and/or S. Halle Vakani of Wyrick Robbins Yates & Ponton LLP to orally modify or withdraw this request for acceleration.
Once the Registration Statement is effective, please orally confirm the event with our counsel, Wyrick Robbins Yates & Ponton LLP, by calling Lorna A. Knick (919) 865-2823. We also respectfully request that a copy of the written order from the Commission verifying the effective date and time of the Registration Statement be sent to Ms. Knick via email at lknick@wyrick.com.
Very truly yours,
TENAX THERAPEUTICS, INC.
By:
/s/ Christopher T. Giordano
Christopher T. Giordano
President and Chief Executive Officer
cc: Lorna A. Knick, Wyrick Robbins Yates & Ponton LLP